. 2014 Jun 5;25(9):2245–2253. doi: 10.1007/s00198-014-2756-8

Table 1.

Demographic and baseline characteristics of study patients

Items	Unit	Total (n = 397)	Switch (n = 264)	Continue (n = 133)	p value^†
Demographic characteristics
Age	Years (min, max)	76.0 ± 7.8 (54, 98)	75.9 ± 7.6 (54, 96)	76.0 ± 8.1 (55, 98)	N. S.
Sex	Female (%)	374 (94.2 %)	252 (95.5 %)	122 (91.7 %)	N. S.
Current bisphosphonate medication	Daily regimen Alendronate Risedronate Minodronate	84 (21.2 %) 11 5 68	54 (20.5 %) 7 2 45	30 (22.6 %) 4 3 23	N. S.
Weekly regimen Alendronate Risedronate	313 (78.8 %) 228 85	210 (79.5 %) 157 53	103 (77.4 %) 71 32	N. S.
BMI	(kg/m²) (min, max)	22.9 ± 3.4 (14.4, 34.3)	23.0 ± 3.5 (14.4, 34.3)	22.5 ± 3.1 (16.9, 32.9)	N. S.
Previous fracture	Yes	170 (42.8 %)	106 (40.2 %)	63 (47.4 %)	N. S.
Spine Hip joint Wrist joint Other	126 17 15 22	80 8 12 14	46 9 3 8	N. S.
Comorbidity	Yes	185 (46.6 %)	118 (44.7 %)	67 (50.4 %)	N. S.
Diabetes M. Renal disease Rheumatism Hyperlipidemia Hypertension Arteriosclerosis	25 3 10 39 119 19	14 1 4 23 74 8	11 2 6 16 45 11	N. S.
Concomitant medication	Yes	310 (78.1 %)	206 (78.0 %)	104 (78.2 %)	N. S.
Vitamin D Vitamin K Calcitonin Calcium agents	229 22 8 113	154 13 8 84	75 9 0 29	N. S.
PPI H₂ blocker Gastroprotectives PGE₂ derivatives	36 31 52 26	25 14 30 19	11 17 22 7	N. S.
NSAIDs	66 (16.6 %)	45 (17.0 %)	21 (15.8 %)	N. S.
Glucocorticoids	3 (0.8 %)	3 (1.1 %)	0 (0.0 %)	N. S.
Baseline characteristics
Back pain VAS score	(mm) (min, max)	26.1 ± 20.9 (0, 80)	27.9 ± 20.8 (0, 79)	22.6 ± 20.7 (0, 80)	0.010*
Abdominal symptoms score	Heartburn (min, max) Epigastralgia (min, max) Epigastric fullness (min, max)	1.34 ± 2.01 (0, 9) 0.85 ± 1.75 (0, 13) 1.22 ± 1.97 (0, 10)	1.38 ± 1.98 (0, 8) 0.89 ± 1.78 (0, 13) 1.24 ± 1.90 (0, 10)	1.26 ± 2.06 (0, 9) 0.76 ± 1.68 (0, 8) 1.17 ± 2.11 (0, 10)	N. S. N. S. N. S.
BMD (lumbar spine)	(g/cm²) (n)	0.768 ± 0.139 (247)	0.767 ± 0.141 (167)	0.770 ± 0.136 (80)	N. S.
(YAM%) (n)	75.6 ± 13.4 (247)	75.6 ± 13.7 (167)	75.4 ± 12.8 (80)	N. S.
BMD (total hip)	(g/cm²) (n)	0.617 ± 0.098 (107)	0.622 ± 0.088 (56)	0.611 ± 0.110 (51)	N. S.
(YAM%) (n)	70.7 ± 11.2 (107)	71.8 ± 9.6 (56)	70.3 ± 12.8 (51)	N. S.
BMD (femoral neck)	(g/cm²) (n)	0.534 ± 0.091 (150)	0.527 ± 0.087 (88)	0.545 ± 0.095 (62)	N. S.
(YAM%) (n)	66.6 ± 10.3 (150)	65.7 ± 9.6 (88)	67.9 ± 11.1 (62)	N. S.
BMD (distal radius)	(g/cm²) (n)	0.455 ± 0.072 (60)	0.455 ± 0.076 (45)	0.453 ± 0.062 (15)	N. S.
(YAM%) (n)	69.9 ± 11.1 (60)	70.0 ± 11.7 (45)	69.7 ± 9.6 (15)	N. S.

Items

Unit

Total (n = 397)

Switch (n = 264)

Continue (n = 133)

p value^†

Demographic characteristics

Age

Years

(min, max)

76.0 ± 7.8

(54, 98)

75.9 ± 7.6

(54, 96)

76.0 ± 8.1

(55, 98)

N. S.

Sex

Female

(%)

374

(94.2 %)

252

(95.5 %)

122

(91.7 %)

N. S.

Current bisphosphonate medication

Daily regimen

Alendronate

Risedronate

Minodronate

84 (21.2 %)

54 (20.5 %)

30 (22.6 %)

N. S.

Weekly regimen

Alendronate

Risedronate

313 (78.8 %)

228

210 (79.5 %)

157

103 (77.4 %)

N. S.

BMI

(kg/m²)

(min, max)

22.9 ± 3.4

(14.4, 34.3)

23.0 ± 3.5

(14.4, 34.3)

22.5 ± 3.1

(16.9, 32.9)

N. S.

Previous fracture

Yes

170 (42.8 %)

106 (40.2 %)

63 (47.4 %)

N. S.

Spine

Hip joint

Wrist joint

Other

126

N. S.

Comorbidity

Yes

185 (46.6 %)

118 (44.7 %)

67 (50.4 %)

N. S.

Diabetes M.

Renal disease

Rheumatism

Hyperlipidemia

Hypertension

Arteriosclerosis

119

N. S.

Concomitant medication

Yes

310 (78.1 %)

206 (78.0 %)

104 (78.2 %)

N. S.

Vitamin D

Vitamin K

Calcitonin

Calcium agents

229

113

154

N. S.

PPI

H₂ blocker

Gastroprotectives

PGE₂ derivatives

N. S.

NSAIDs

66 (16.6 %)

45 (17.0 %)

21 (15.8 %)

N. S.

Glucocorticoids

3 (0.8 %)

3 (1.1 %)

0 (0.0 %)

N. S.

Baseline characteristics

Back pain VAS score

(mm)

(min, max)

26.1 ± 20.9

(0, 80)

27.9 ± 20.8

(0, 79)

22.6 ± 20.7

(0, 80)

0.010*

Abdominal symptoms score

Heartburn

(min, max)

Epigastralgia

(min, max)

Epigastric fullness

(min, max)

1.34 ± 2.01

(0, 9)

0.85 ± 1.75

(0, 13)

1.22 ± 1.97

(0, 10)

1.38 ± 1.98

(0, 8)

0.89 ± 1.78

(0, 13)

1.24 ± 1.90

(0, 10)

1.26 ± 2.06

(0, 9)

0.76 ± 1.68

(0, 8)

1.17 ± 2.11

(0, 10)

N. S.

BMD (lumbar spine)

(g/cm²)

(n)

0.768 ± 0.139

(247)

0.767 ± 0.141

(167)

0.770 ± 0.136

(80)

N. S.

(YAM%)

(n)

75.6 ± 13.4

(247)

75.6 ± 13.7

(167)

75.4 ± 12.8

(80)

N. S.

BMD (total hip)

(g/cm²)

(n)

0.617 ± 0.098

(107)

0.622 ± 0.088

(56)

0.611 ± 0.110

(51)

N. S.

(YAM%)

(n)

70.7 ± 11.2

(107)

71.8 ± 9.6

(56)

70.3 ± 12.8

(51)

N. S.

BMD (femoral neck)

(g/cm²)

(n)

0.534 ± 0.091

(150)

0.527 ± 0.087

(88)

0.545 ± 0.095

(62)

N. S.

(YAM%)

(n)

66.6 ± 10.3

(150)

65.7 ± 9.6

(88)

67.9 ± 11.1

(62)

N. S.

BMD (distal radius)

(g/cm²)

(n)

0.455 ± 0.072

(60)

0.455 ± 0.076

(45)

0.453 ± 0.062

(15)

N. S.

(YAM%)

(n)

69.9 ± 11.1

(60)

70.0 ± 11.7

(45)

69.7 ± 9.6

(15)

N. S.

Data are expressed as mean ± standard deviation unless otherwise indicated

BMI body mass index, Diabetes M. diabetes mellitus, PPI proton pump inhibitor, NSAID non-steroidal anti-inflammatory drug, VAS visual analogue scale, BMD bone mass density, YAM young adult mean

^†Comparison between Switch group and Continue group

*Statistically significant (α = 0.05) as analyzed by Wilcoxon rank-sum test

N. S. statistically not significant as analyzed by Wilcoxon rank-sum test or chi-square test